The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...

AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete ...

The collaboration between companies holds both scientific and strategic rationale as the objective of the collaboration is to advance an intranasal MEAI formulation to support Clearmind’s future ...

Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...

The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

Biocomposites Stimulan are commonly used in orthopaedic reconstruction, trauma, diabetic foot osteomyelitis (DFO) procedures.

AstraZeneca has already provided the requested information to the FDA and a decision on the updated BLA is expected in the first half of 2026.

Hårklinikken’s clinically backed formula is helping women regrow hair through a multifactorial approach leading to long term ...

Seed Treatment Fungicides Market shows steady expansion driven by rising global food demand, yield protection priorities, and intensifying pressure from soil-borne pathogens. Adoption across cereals, ...

In his post, Makary said, “FDA will take swift action against companies’ mass-marketing illegal copycat drugs, claiming they ...

Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind's lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE ...